Talis Biomedical Corporation

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 14:40:33 05/06/2024 BST			5-day change	1st Jan Change
9 ^USD	-3.07%		-1.10%	+20.81%

05-08	Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-02	North American Morning Briefing : Stocks Seen -2-	DJ

Talis Biomedical Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2021

March 15, 2022 at 08:08 pm

Talis Biomedical Corporation reported earnings results for the fourth quarter ended December 31, 2021. For the fourth quarter, the company reported net loss was USD 28.65 million compared to USD 44.2 million a year ago.

Latest news about Talis Biomedical Corporation

Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Talis Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	11-22	DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Talis Biomedical Announces Exploration of Strategic Alternatives	11-13	CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee	01/09/23	CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating	16/08/23	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023	10/08/23
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer	02/08/23	CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels	27/07/23	CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors	23/05/23	CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023	11/05/23
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director	08/05/23	CI
Talis Biomedical Corporation Announces Executive Changes	11/04/23	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Reports Q4 Revenue $0.3M	22/03/23	MT
North American Morning Briefing : Stock Futures -2-	21/03/23	DJ
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors	10/03/23	CI
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q3 Revenue $796,000	03/11/22	MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	02/08/22	CI
Transcript : Talis Biomedical Corporation, Q2 2022 Earnings Call, Aug 02, 2022	02/08/22
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q2 Revenue $0.6M	02/08/22	MT

Chart Talis Biomedical Corporation

Duration

Period

More charts

Company Profile

Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.

Sector

Biotechnology & Medical Research

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TALIS BIOMEDICAL CORPORATION	+20.81%	16.92M
MODERNA, INC.	+50.25%	55.7B
LONZA GROUP AG	+39.89%	39.91B
IQVIA HOLDINGS INC.	-6.49%	39.57B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+14.11%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-20.94%	18.94B
MEDPACE HOLDINGS, INC.	+30.85%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.69%	12.12B
BIO-TECHNE CORPORATION	+0.35%	12.12B

Other Biotechnology & Medical Research